Methods of use of soluble CD24 for therapy of rheumatoid arthritis
US10793617B2 · kind B2 · utility
0Cited by
4References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 16, 2018 |
| Grant date | Oct 6, 2020 |
| Priority date | — |
| Expiry date | Aug 16, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.